Sulforaphane diminishes moonlighting of pyruvate kinase M2 and interleukin 1β expression in M1 (LPS) macrophages

Bibliographic Details
Title: Sulforaphane diminishes moonlighting of pyruvate kinase M2 and interleukin 1β expression in M1 (LPS) macrophages
Authors: Sheyda Bahiraii, Martin Brenner, Fangfang Yan, Wolfram Weckwerth, Elke H. Heiss
Source: Frontiers in Immunology, Vol 13 (2022)
Publisher Information: Frontiers Media S.A., 2022.
Publication Year: 2022
Collection: LCC:Immunologic diseases. Allergy
Subject Terms: sulforaphane, macrophages, M1 polarization, glycolysis, PKM2, interleukin 1 beta, Immunologic diseases. Allergy, RC581-607
More Details: Murine macrophages activated by the Toll-like receptor 4 agonist lipopolysaccharide (LPS) polarize to the M1 type by inducing proinflammatory marker proteins and changing their energy metabolism to increased aerobic glycolysis and reduced respiration. We here show that the aliphatic isothiocyanate sulforaphane (Sfn) diminishes M1 marker expression (IL-1β, IL-6, TNF-α, iNOS, NO, and ROS) and leads to highly energetic cells characterized by both high glycolytic and high respiratory activity as assessed by extracellular flux analysis. Focusing on a potential connection between high glycolytic activity and low IL-1β expression in M1 (LPS/Sfn) macrophages, we reveal that Sfn impedes the moonlighting function of pyruvate kinase M2 (PKM2) in M1 macrophages. Sfn limits mono/dimerization and nuclear residence of PKM2 accompanied by reduced HIF-1α levels, Stat3 phosphorylation at tyrosine 705, and IL-1β expression while preserving high levels of cytosolic PKM2 tetramer with high glycolytic enzyme activity. Sfn prevents glutathionylation of PKM2 in LPS-stimulated macrophages which may account for the reduced loss of PKM2 tetramer. Overall, we uncover PKM2 as a novel affected hub within the anti-inflammatory activity profile of Sfn.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1664-3224
Relation: https://www.frontiersin.org/articles/10.3389/fimmu.2022.935692/full; https://doaj.org/toc/1664-3224
DOI: 10.3389/fimmu.2022.935692
Access URL: https://doaj.org/article/2bdd16a2eb9642bd8caac484a9125978
Accession Number: edsdoj.2bdd16a2eb9642bd8caac484a9125978
Database: Directory of Open Access Journals
More Details
ISSN:16643224
DOI:10.3389/fimmu.2022.935692
Published in:Frontiers in Immunology
Language:English